DE69834508D1 - Aptoptoseinhibitoren - Google Patents

Aptoptoseinhibitoren

Info

Publication number
DE69834508D1
DE69834508D1 DE69834508T DE69834508T DE69834508D1 DE 69834508 D1 DE69834508 D1 DE 69834508D1 DE 69834508 T DE69834508 T DE 69834508T DE 69834508 T DE69834508 T DE 69834508T DE 69834508 D1 DE69834508 D1 DE 69834508D1
Authority
DE
Germany
Prior art keywords
substituted
group
compound
formula
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69834508T
Other languages
English (en)
Other versions
DE69834508T2 (de
Inventor
Junji Matsui
Naoki Tarui
Yu Momose
Ken-Ichi Naruo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69834508D1 publication Critical patent/DE69834508D1/de
Publication of DE69834508T2 publication Critical patent/DE69834508T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69834508T 1997-11-19 1998-11-18 Apoptoseinhibitoren Expired - Lifetime DE69834508T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31792697 1997-11-19
JP31792697 1997-11-19
PCT/JP1998/005178 WO1999025346A1 (en) 1997-11-19 1998-11-18 Novel apoptosis inhibitors

Publications (2)

Publication Number Publication Date
DE69834508D1 true DE69834508D1 (de) 2006-06-14
DE69834508T2 DE69834508T2 (de) 2006-11-23

Family

ID=18093586

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834508T Expired - Lifetime DE69834508T2 (de) 1997-11-19 1998-11-18 Apoptoseinhibitoren

Country Status (8)

Country Link
US (3) US6087384A (de)
EP (1) EP1047423B1 (de)
AT (1) ATE325607T1 (de)
AU (1) AU1172999A (de)
CA (1) CA2311125C (de)
DE (1) DE69834508T2 (de)
ES (1) ES2259459T3 (de)
WO (1) WO1999025346A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323889A1 (en) * 1997-03-12 1998-09-17 Robert W. Esmond A method for treating or preventing alzheimer's disease
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
TR200100207T2 (tr) * 1998-07-21 2001-05-21 Smithkline Beecham P.L.C. Apoptozun redüksiyonu için glükoz alımını kuvvetlendirici maddenin kullanıması
US20020099082A1 (en) * 1998-07-21 2002-07-25 Smithkline Beecham P.L.C. Use of glucose uptake enhancer for reducing apoptosis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2000043007A1 (fr) * 1999-01-19 2000-07-27 Sankyo Company, Limited Compositions médicinales à base de troglitazone inhibitrices de l'apoptose
WO2001062238A2 (en) * 2000-02-24 2001-08-30 San Diego State University Ppar gamma agonists for the treatment of liver inflammatory disorders
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
FR2841141A1 (fr) * 2002-06-24 2003-12-26 Exonhit Therapeutics Sa Nouvelles approches therapeutiques de la sclerose lateral amyotrophique
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
GB0324574D0 (en) * 2003-10-21 2003-11-26 Glaxo Group Ltd Novel compositions
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
EP1732513A2 (de) * 2003-12-31 2006-12-20 Alpharma, Inc. Formulierungen von rosiglitazon
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
WO2009043593A1 (en) * 2007-10-05 2009-04-09 Merz Pharma Gmbh & Co. Kgaa Combination therapy using memantine and glitazones
US8337896B2 (en) 2007-12-13 2012-12-25 Kyushu University, National University Corporation Drug-containing nanoparticles
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
NZ619895A (en) * 2008-08-12 2015-12-24 Zinfandel Pharmaceuticals Inc Method of identifying disease risk factors
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
GB201805554D0 (en) * 2018-04-04 2018-05-16 Wren Therapeutics Therapy for protein misfolding disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
SE9302332D0 (sv) * 1993-07-06 1993-07-06 Ab Astra New compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
JP3029768B2 (ja) * 1994-04-18 2000-04-04 三共株式会社 悪液質改善剤
IT1280417B1 (it) * 1995-04-14 1998-01-20 Alfa Wassermann Spa Composti a struttura 3,4 diidro-2-iodometil-2,5,7,8-tetrametil-2h-1 benzopiranica.
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
JPH09323930A (ja) * 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
JPH09291031A (ja) * 1996-04-24 1997-11-11 Yamanouchi Pharmaceut Co Ltd 脂質代謝改善剤
US6242196B1 (en) * 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
GEP20033045B (en) * 1998-09-17 2003-08-25 Bristol Myers Squibb Co Method for Treating Diabetes
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
EP1047423B1 (de) 2006-05-10
WO1999025346A1 (en) 1999-05-27
US20020086883A1 (en) 2002-07-04
CA2311125A1 (en) 1999-05-27
US6087384A (en) 2000-07-11
EP1047423A1 (de) 2000-11-02
DE69834508T2 (de) 2006-11-23
AU1172999A (en) 1999-06-07
ES2259459T3 (es) 2006-10-01
US6399639B1 (en) 2002-06-04
ATE325607T1 (de) 2006-06-15
CA2311125C (en) 2011-01-18
US6555565B2 (en) 2003-04-29

Similar Documents

Publication Publication Date Title
DE69834508D1 (de) Aptoptoseinhibitoren
TW370450B (en) Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives
CA2116387A1 (en) Oxazolidinedione derivatives, their production and use
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
TR200000946T2 (tr) İkameli füzyonlu heterosiklik bileşimi
ID17851A (id) Persenyawaan heterosiklis, produksi dan pemakaiannya
WO1999009965A3 (en) Anti-inflammatory agent
DE69133299D1 (de) Aminosulfonylcarbamate
DK249089D0 (da) Benzamid-forbindelser, der er nyttige som protease-inhibitorer
ATE234298T1 (de) Zyklische etherverbindungen als natriumkanal- modulatoren
ES2044013T3 (es) Compuesto mesomorfico, una composicion de cristal liquido que contiene el compuesto y un dispositivo de cristal liquido que utiliza la composicion.
ES8705442A1 (es) Un procedimiento para preparar compuestos de carbapenem
DE60239170D1 (de) Bicyclische Verbindungen
MY100115A (en) Nitrogen containing heterocyclic compounds, and their production and use.
TR200200360T2 (tr) Antibakteriyel aktif maddeler.
KR860700250A (ko) 신규 아미딘 화합물
ATE247660T1 (de) Furopyridinderivate und ihre therapeutische verwendung
LV10076A (lv) Aizvietoti beta- diketoni
SE8203877L (sv) Aminosulfonylbensoesyraderivat
MX170732B (es) Composicion de derivados de succinimida y su uso
MX9700365A (es) Uso de benzaldehidos para asignar hidrocarburos.
NO913768L (no) Forbindelse, anvendelse og fremstilling.
ES459755A1 (es) Procedimiento para preparar carbamatos de oximas de deriva- dos del acido isonitrosocianocetico.
DE60112917D1 (de) Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität
ATE7786T1 (de) Verwendung von wachstumsregulierenden alphaazolylglykolen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition